Table 2.
Clinical-pathological data of lung adenocarcinoma (LUAD) from The Cancer Genome Atlas (TCGA) dataset.
| Characteristics | Total | Characteristics | Total |
|---|---|---|---|
| All Stages | Non-Metastatic Disease | ||
| Cohort size (n) | 617 | 128 | |
| Age at diagnosis Mean ± devst |
65.94 ± 9.88 | Age at diagnosis Mean ± devst |
64.55 ± 9.82 |
| Sex | Sex | ||
| Male | 284 (46%) | Male | 60 (46.9%) |
| Female | 333 (54%) | Female | 68 (53.1%) |
| Race | Race | ||
| White | 465 (75.4%) | White | 101 (78.9%) |
| Black or African American | 59 (9.6%) | Black or African American | 19 (14.8%) |
| Asian | 10 (1.6%) | Asian | 2 (1.6%) |
| NA | 83 (13.5%) | NA | 6 (4.7%) |
| Number of packs/year Mean ± SD |
41.63 ± 27.22 | Number of packs/year Mean ± SD |
41.62 ± 24.71 |
| Stage of disease | Stage of disease | ||
| Stage I | 5 (0.8%) | Stage I | 1 (0.8%) |
| Stage IA | 164 (26.6%) | Stage IA | 47 (36.7%) |
| Stage IB | 163 (26.4%) | Stage IB | 30 (23.4%) |
| Stage II | 1 (0.2%) | Stage II | 1 (0.8%) |
| Stage IIA | 63 (10.2%) | Stage IIA | 22 (17.2%) |
| Stage IIB | 87 (14.1%) | Stage IIB | 14 (10.9%) |
| Stage IIIA | 98 (15.9%) | Stage IIIA | 13 (10.2%) |
| Stage IV | 28 (4.5%) | ||
| NA | 8 (1.3%) | ||
SD, standard deviation.